Viamet raises $4M for metalloenzyme-targeting drugs
Research Triangle Park, N.C.-based Viamet raised $4 million in a first round of funding. The round was co-led by Hatteras Venture Partners and Intersouth Partners.
Viamet is developing drugs that target metalloenzymes — a diverse group of catalyst molecules that include metal atoms — in infectious disease, inflammation and cancer. The company was founded in 2005.
Next Story: Amgen snaps up another biotech startup, Alantos Pharma, for $300M
Previous Story: Biomarker-diagnostics developer Singulex validates $19M
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.